181 related articles for article (PubMed ID: 15456460)
1. Review article: gastric pH -- the most relevant predictor of benefit in reflux disease?
Armstrong D
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():19-26; discussion 38-9. PubMed ID: 15456460
[TBL] [Abstract][Full Text] [Related]
2. Review article: intragastric and oesophageal pH monitoring in patients with gastro-oesophageal reflux disease.
Katz PO
Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():3-11. PubMed ID: 16483265
[TBL] [Abstract][Full Text] [Related]
3. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
Huang JQ; Hunt RH
Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
[TBL] [Abstract][Full Text] [Related]
5. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux.
Miner PB
Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():25-32. PubMed ID: 16483267
[TBL] [Abstract][Full Text] [Related]
6. pH, healing rate, and symptom relief in patients with GERD.
Huang JQ; Hunt RH
Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
[TBL] [Abstract][Full Text] [Related]
7. Review article: is stringent control of gastric pH useful and practical in GERD?
Kahrilas PJ
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():89-94; discussion 95-6. PubMed ID: 15456470
[TBL] [Abstract][Full Text] [Related]
8. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
[TBL] [Abstract][Full Text] [Related]
9. Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
Frazzoni M; Manno M; De Micheli E; Savarino V
Dig Liver Dis; 2006 Feb; 38(2):85-90. PubMed ID: 16289976
[TBL] [Abstract][Full Text] [Related]
10. Review article: Helicobacter pylori and gastro-oesophageal reflux disease.
Delaney B; McColl K
Aliment Pharmacol Ther; 2005 Aug; 22 Suppl 1():32-40. PubMed ID: 16042657
[TBL] [Abstract][Full Text] [Related]
11. Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications.
Robinson M
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():1-10. PubMed ID: 15496213
[TBL] [Abstract][Full Text] [Related]
12. Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.
Robinson M
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():30-7. PubMed ID: 15496216
[TBL] [Abstract][Full Text] [Related]
13. Histamine receptor antagonists, proton pump inhibitors and their combination in the treatment of gastro-oesophageal reflux disease.
Katz PO; Tutuian R
Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):371-84. PubMed ID: 11403533
[TBL] [Abstract][Full Text] [Related]
14. Normalization of oesophageal pH does not guarantee control of duodenogastro-oesophageal reflux in Barrett's oesophagus.
Todd JA; Basu KK; de Caestecker JS
Aliment Pharmacol Ther; 2005 Apr; 21(8):969-75. PubMed ID: 15813832
[TBL] [Abstract][Full Text] [Related]
15. Nocturnal gastric acidity pattern in gastro-oesophageal reflux disease with or without oesophagitis.
Sozzi M; Valentini M; Poletti M; Bertolissi E; Serraino D; Bovero E; De Iaco F
Ital J Gastroenterol; 1995; 27(8):413-8. PubMed ID: 8775466
[TBL] [Abstract][Full Text] [Related]
16. Correlation between gastric pH and gastro-oesophageal reflux contents: ambulatory pH-impedance monitoring results.
Roman S; Serraj I; Damon H; Mion F
Neurogastroenterol Motil; 2007 Jul; 19(7):562-8. PubMed ID: 17593137
[TBL] [Abstract][Full Text] [Related]
17. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups.
Shapiro M; Green C; Faybush EM; Esquivel RF; Fass R
Aliment Pharmacol Ther; 2006 Jan; 23(2):321-9. PubMed ID: 16393313
[TBL] [Abstract][Full Text] [Related]
18. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
[TBL] [Abstract][Full Text] [Related]
19. Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor.
Gardner JD; Sloan S; Robinson M; Miner PB
Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1381-6. PubMed ID: 15606401
[TBL] [Abstract][Full Text] [Related]
20. 24-h recording of intragastric pH: technical aspects and clinical relevance.
van Herwaarden MA; Samsom M; Smout AJ
Scand J Gastroenterol Suppl; 1999; 230():9-16. PubMed ID: 10499456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]